Orna Therapeutics, a pioneer in the field of circular RNA therapeutics, has officially announced its acquisition of ReNAgade Therapeutics, a company renowned for its significant advancements in RNA delivery systems. This strategic move aims to reshape the landscape of RNA medicine by integrating and amplifying the capabilities and technologies of both entities. Following this acquisition, […]
In a significant advancement for the pharmaceutical and biotechnology industry, Thermo Fisher Scientific, a global leader in scientific services, has received Good Manufacturing Practice (GMP) approval from the Italian Medicines Agency (AIFA). This certification allows the company’s Monza, Italy facility to manufacture RNA-based products, marking a pivotal moment for Thermo Fisher Scientific and the broader […]
In an ambitious move within the biotechnology sector, a new U.S. biotech company, Twentyeight-Seven Therapeutics (28-7), has been established in Cambridge with a primary focus on developing therapies for cancer and other diseases by modulating non-coding RNA (ncRNA). Coinciding with its launch, Twentyeight-Seven Therapeutics announced a successful $65 million Series A financing round led by […]